New Horizons: Emerging Antidiabetic Medications
Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkabl...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2022-12, Vol.107 (12), p.e4333-e4340 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e4340 |
|---|---|
| container_issue | 12 |
| container_start_page | e4333 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 107 |
| creator | Mingrone, Geltrude Castagneto-Gissey, Lidia Bornstein, Stefan R |
| description | Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss.
An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity, with stunning results that are similar to the effects of metabolic surgery.
An important role of antidiabetic medications is to reduce the risk and improve the outcome of cardiovascular diseases, including coronary artery disease and heart failure with reduced or preserved ejection fraction, as well as diabetic nephropathy, as shown by SGLT2 inhibitors.
This review summarizes the main drugs currently under development for the treatment of type 1 diabetes and T2D, highlighting their strengths and side effects. |
| doi_str_mv | 10.1210/clinem/dgac499 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2714657773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A777587371</galeid><sourcerecordid>A777587371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-926c780d166a3c4a4f5d6f2743bddae4dab859bde3cb5eab7a1cdb55038bb35b3</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgCs7p1XPBi5duSZM0jbcxphOmXhS8hfx4LZE2nUmH6F9vx3Yc7_Dg8XnfwxehW4JnpCB4blsfoJu7Rlsm5RmaEMl4LogU52iCcUFyKYrPS3SV0hfGhDFOJ2j-Cj_Zuo_-rw_pIVt1EBsfmmwRBu-8NjB4m72A81YPfiTX6KLWbYKb456ij8fV-3Kdb96enpeLTW7H3CGXRWlFhR0pS00t06zmrqwLwahxTgNz2lRcGgfUGg7aCE2sM5xjWhlDuaFTdH_I3cb-ewdpUJ1PFtpWB-h3SRWCsJILIehI7w600S0oH-p-iNruuVqMgFeCCjKq2Qk1joPO2z5A7cf7qQcb-5Qi1GobfafjryJY7QtXh8LVsXD6D9fzdQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714657773</pqid></control><display><type>article</type><title>New Horizons: Emerging Antidiabetic Medications</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Mingrone, Geltrude ; Castagneto-Gissey, Lidia ; Bornstein, Stefan R</creator><creatorcontrib>Mingrone, Geltrude ; Castagneto-Gissey, Lidia ; Bornstein, Stefan R</creatorcontrib><description>Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss.
An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity, with stunning results that are similar to the effects of metabolic surgery.
An important role of antidiabetic medications is to reduce the risk and improve the outcome of cardiovascular diseases, including coronary artery disease and heart failure with reduced or preserved ejection fraction, as well as diabetic nephropathy, as shown by SGLT2 inhibitors.
This review summarizes the main drugs currently under development for the treatment of type 1 diabetes and T2D, highlighting their strengths and side effects.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgac499</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Alefacept ; Coronary heart disease ; Development and progression ; Dextrose ; Diabetes ; Diabetes therapy ; Fatty acids ; G proteins ; Glucagon ; Glucose ; Glycosylated hemoglobin ; Heart failure ; Hyperglycemia ; Hypoglycemic agents ; Insulin resistance ; Isoenzymes ; Kidney diseases ; Membrane proteins</subject><ispartof>The journal of clinical endocrinology and metabolism, 2022-12, Vol.107 (12), p.e4333-e4340</ispartof><rights>COPYRIGHT 2022 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-926c780d166a3c4a4f5d6f2743bddae4dab859bde3cb5eab7a1cdb55038bb35b3</citedby><cites>FETCH-LOGICAL-c445t-926c780d166a3c4a4f5d6f2743bddae4dab859bde3cb5eab7a1cdb55038bb35b3</cites><orcidid>0000-0003-2021-528X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mingrone, Geltrude</creatorcontrib><creatorcontrib>Castagneto-Gissey, Lidia</creatorcontrib><creatorcontrib>Bornstein, Stefan R</creatorcontrib><title>New Horizons: Emerging Antidiabetic Medications</title><title>The journal of clinical endocrinology and metabolism</title><description>Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss.
An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity, with stunning results that are similar to the effects of metabolic surgery.
An important role of antidiabetic medications is to reduce the risk and improve the outcome of cardiovascular diseases, including coronary artery disease and heart failure with reduced or preserved ejection fraction, as well as diabetic nephropathy, as shown by SGLT2 inhibitors.
This review summarizes the main drugs currently under development for the treatment of type 1 diabetes and T2D, highlighting their strengths and side effects.</description><subject>Alefacept</subject><subject>Coronary heart disease</subject><subject>Development and progression</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Diabetes therapy</subject><subject>Fatty acids</subject><subject>G proteins</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Glycosylated hemoglobin</subject><subject>Heart failure</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic agents</subject><subject>Insulin resistance</subject><subject>Isoenzymes</subject><subject>Kidney diseases</subject><subject>Membrane proteins</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpt0M9LwzAUB_AgCs7p1XPBi5duSZM0jbcxphOmXhS8hfx4LZE2nUmH6F9vx3Yc7_Dg8XnfwxehW4JnpCB4blsfoJu7Rlsm5RmaEMl4LogU52iCcUFyKYrPS3SV0hfGhDFOJ2j-Cj_Zuo_-rw_pIVt1EBsfmmwRBu-8NjB4m72A81YPfiTX6KLWbYKb456ij8fV-3Kdb96enpeLTW7H3CGXRWlFhR0pS00t06zmrqwLwahxTgNz2lRcGgfUGg7aCE2sM5xjWhlDuaFTdH_I3cb-ewdpUJ1PFtpWB-h3SRWCsJILIehI7w600S0oH-p-iNruuVqMgFeCCjKq2Qk1joPO2z5A7cf7qQcb-5Qi1GobfafjryJY7QtXh8LVsXD6D9fzdQw</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Mingrone, Geltrude</creator><creator>Castagneto-Gissey, Lidia</creator><creator>Bornstein, Stefan R</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2021-528X</orcidid></search><sort><creationdate>20221201</creationdate><title>New Horizons: Emerging Antidiabetic Medications</title><author>Mingrone, Geltrude ; Castagneto-Gissey, Lidia ; Bornstein, Stefan R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-926c780d166a3c4a4f5d6f2743bddae4dab859bde3cb5eab7a1cdb55038bb35b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alefacept</topic><topic>Coronary heart disease</topic><topic>Development and progression</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Diabetes therapy</topic><topic>Fatty acids</topic><topic>G proteins</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Glycosylated hemoglobin</topic><topic>Heart failure</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic agents</topic><topic>Insulin resistance</topic><topic>Isoenzymes</topic><topic>Kidney diseases</topic><topic>Membrane proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mingrone, Geltrude</creatorcontrib><creatorcontrib>Castagneto-Gissey, Lidia</creatorcontrib><creatorcontrib>Bornstein, Stefan R</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mingrone, Geltrude</au><au>Castagneto-Gissey, Lidia</au><au>Bornstein, Stefan R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Horizons: Emerging Antidiabetic Medications</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><date>2022-12-01</date><risdate>2022</risdate><volume>107</volume><issue>12</issue><spage>e4333</spage><epage>e4340</epage><pages>e4333-e4340</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss.
An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity, with stunning results that are similar to the effects of metabolic surgery.
An important role of antidiabetic medications is to reduce the risk and improve the outcome of cardiovascular diseases, including coronary artery disease and heart failure with reduced or preserved ejection fraction, as well as diabetic nephropathy, as shown by SGLT2 inhibitors.
This review summarizes the main drugs currently under development for the treatment of type 1 diabetes and T2D, highlighting their strengths and side effects.</abstract><pub>Oxford University Press</pub><doi>10.1210/clinem/dgac499</doi><orcidid>https://orcid.org/0000-0003-2021-528X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2022-12, Vol.107 (12), p.e4333-e4340 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2714657773 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Alefacept Coronary heart disease Development and progression Dextrose Diabetes Diabetes therapy Fatty acids G proteins Glucagon Glucose Glycosylated hemoglobin Heart failure Hyperglycemia Hypoglycemic agents Insulin resistance Isoenzymes Kidney diseases Membrane proteins |
| title | New Horizons: Emerging Antidiabetic Medications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A10%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Horizons:%20Emerging%20Antidiabetic%20Medications&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Mingrone,%20Geltrude&rft.date=2022-12-01&rft.volume=107&rft.issue=12&rft.spage=e4333&rft.epage=e4340&rft.pages=e4333-e4340&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgac499&rft_dat=%3Cgale_proqu%3EA777587371%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714657773&rft_id=info:pmid/&rft_galeid=A777587371&rfr_iscdi=true |